Background Some biologics for psoriasis, especially anti-tumor necrosis factor (TNF)-α
therapies, may re-activate latent tuberculosis (TBC) infection with consequent morbidity and …

Upon the association of biologic treatments with reactivation of latent tuberculosis infection
(LTBI), screening for Mycobacterium tuberculosis infection and anti-tuberculosis …

Introduction The utilization of biologics in patients with psoriasis with latent tuberculosis
infection (LTBI) has garnered significant attention. Although the tuberculosis (TB) safety …

Importance Approximately one-quarter of the global population have latent tuberculosis
infection (LTBI), and tuberculosis (TB) is accountable for more than 1.5 million deaths …

Introduction The tuberculosis (TB) positive conversion rate among psoriasis patients who
received biologics has been reported worldwide, particularly in regions with low TB risk …

Background: There is limited long-term, real-world evidence on the efficacy and safety in
patients with plaque psoriasis treated with secukinumab. We present results at 136 weeks in …

Background There are limited data regarding the long‐term continuation with biological
therapy for patients with psoriasis. In particular, the reasons for secukinumab discontinuation …

Background Patients treated with tumour necrosis factor (TNF) inhibitors are at risk of new‐
onset tuberculosis (TB) or reactivation of latent tuberculosis infection (LTBI). Association …

Abstract Background and Objective Biologics for psoriasis, especially anti-tumor necrosis
factor-α therapies, may reactivate hepatitis B virus (HBV) or hepatitis C virus (HCV) …

The tuberculosis (TB) burden is high in China, with a 32% prevalence of latent tuberculosis
infection (LTBI) in Beijing. Screening for LTBI and the chemoprophylaxis of positive patients …